App boosts PrEP use among men and transgender women at high HIV risk

NCT ID NCT06159582

Completed Prevention Sponsor: San Diego State University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a mobile app called eSTEP designed to help men who have sex with men and transgender women at high risk for HIV start and continue taking PrEP, a daily pill or injection that prevents HIV. 113 participants were randomly assigned to use the app plus usual care or just usual care. The app provided tailored support and reminders. Results showed that more people in the app group started PrEP and stayed on it over 24 weeks compared to those receiving usual care alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mobile app (eSTEP)
What this could lead to: If effective, this app could help more people at high risk for HIV start and stick with PrEP, reducing new infections.
What could go wrong: This was a small pilot study (113 people) and the app may not work as well in larger, more diverse groups. The results are promising but need confirmation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRE-EXPOSURE PROPHYLAXIS (PREP) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRE-EXPOSURE PROPHYLAXIS (PREP)

Contacts and locations

Locations

San Diego State University - Department of Psychology

San Diego, California, 92120, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.